To evaluate predictors of intraventricular hemorrhage (IVH) and IVH growth, impact of IVH growth on outcome, and impact of recombinant activated factor VII (rFVIIa) in patients with intracerebral hemorrhage (ICH).
I
ntracerebral hemorrhage (ICH) is the deadliest form of stroke; more than onethird of patients experiencing ICH die within 1 month after symptom onset, and only 20% of patients regain functional independence. The outlook is particularly poor for patients who, in addition, have intraventricular hemorrhage (IVH). Studies have reported that 30 to 50% of patients with spontaneous ICH experience additional IVH (12, 25, 26) , and Tuhrim et al. (26) reported that the 30-day mortality rate for patients with IVH was nearly five times higher than those with ICH alone. Intraventricular blood volume was significantly associated with higher mortality at Day 30. Location of parenchymal origin of ICH, distribution of ventricular blood, and IVH volumes have been reported to be predictors of outcome in patients with spontaneous ICH and intraventricular extension (5, 10, 27) . IVH is an important predictor of 30-day mortality (9) . The development of IVH, therefore, seems to be an important factor in the clinical outcome of ICH patients.
Intuitively, it makes sense that IVH impacts on clinical outcome based on several possible mechanisms. The ventricular system can provide an outlet for ICH expansion with perhaps less resistance than brain parenchyma, and IVH volume can independently exert mass effect on the surrounding brain tissue (3) . In addition, obstruction of the cerebrospinal fluid (CSF) can result in obstructive hydrocephalus, which can raise intracranial pressure and result in global impairment. Last, the presence of blood in the CSF may represent a global injury to the brain, whereas the original ICH may only result in a focal deficit.
Most studies that have investigated the influence of IVH on clinical outcome and mortality have focused on the effect of IVH at one particular time point (26) . However, ICH and IVH are not static events, but rather part of a dynamic process. Brott et al. (3) demonstrated that nearly 40% of patients with an ICH develop an increase in hematoma size within 24 hours, which has been validated in three Japanese studies (7, 8, 11) . These results have been further elaborated by Davis et al. (4) , who, in a quantitative assessment of ICH, showed that 72.9% of patients demonstrate increased hematoma after the baseline computed tomographic (CT) scan. Tuhrim et al. have also found the total volume of ICH on admission to be correlated with the size of IVH.
Surgical approaches have targeted a reduction of blood volume at early and very early time points (16) (17) (18) , but could not demonstrate an effect on mortality or outcome. Hemostatic agents have been studied to attempt to reduce parenchymal hematoma growth (13, 22) . We recently demonstrated that recombinant activated factor VII (rFVIIa) reduces hematoma growth, decreases mortality, and improves clinical outcome when administered within 4 hours of symptom onset of ICH. Treatment with rFVIIa not only reduced parenchymal hemorrhage size, but also total volume increase, which included the parenchymal and intraventricular blood as well as edema volume (13) .
Although it is well established that parenchymal ICH can acutely increase in size, to our knowledge, no studies have focused specifically on the dynamics and clinical impact of early IVH growth in isolation. In this report we aimed to 1) identify factors that influence the dynamics of IVH growth during the acute stage of hemorrhage; 2) analyze the isolated effect of IVH growth on overall mortality and morbidity; and 3) determine the impact of rFVIIa treatment on early IVH growth.
METHODS
This study represents a planned secondary analysis of data from a multicenter, randomized, placebo-controlled trial on the effectiveness of rFVIIa in spontaneous ICH (13) . Patients were included with spontaneous ICH documented by CT scan within 3 hours of onset of symptoms, with exclusion of patients with a Glasgow Coma Score (GCS) of 5 or less; planned surgical hematoma evacuation; secondary ICH related to aneurysm, arteriovenous malformation, trauma, or other causes; known use of oral anticoagulant; known thrombocytopenia; history of coagulopathy, acute sepsis, crush injury, or disseminated intravascular coagulation; pregnancy; preexisting disability modified Rankin scale (mRS) score greater than 2; and symptomatic thrombotic or vaso-occlusive disease (i.e., angina, claudication, deep vein thrombosis, or cerebral or myocardial infarction) within 30 days before the onset ICH. The trial was approved by local institutional review boards and by local and national ethics boards as applicable (13) . In this trial, 399 patients were randomized to receive rFVIIa (40, 80, or 160 g/kg) or placebo administered within 4 hours of ICH symptom onset. CT scans were performed at baseline (admission) and at 24 and 72 hours after treatment. ICH and IVH volumes were calculated using standard planimetric techniques and analyzed by two independent neuroradiologists. These changes in hemorrhage were carefully assessed using planimetric methods in which the inter-reader correlation coefficient for the determination of ICH volume was 0.9596, and the determination of IVH was 0.9468, with an average difference of 0.3 ml between readers, and have been recently published (28) .
Clinical assessments in this analysis were performed at baseline, 24 hours, and 90 days. Neurological deficit was assessed using the National Institute of Health Stroke Scale and level of consciousness using the GCS, whereas functional status was assessed using the mRS, GCS, and the Barthel Index. Clinical outcome at Day 90 was defined with mRS dichotomized into favorable (mRS, 0-3) and poor (mRS, [4] [5] [6] .
The analyses were restricted to the baseline and 24-hour CT scan because a treatment effect is only expected within that time window because of the 2.6-hour half-life of rFVIIa. The three rFVIIa dose groups with and without initial presence of IVH were not appreciably different in sex, age, or baseline ICH volumes, and the frequency of IVH was low. Therefore, for purposes of this IVH analysis, we pooled patients from all three rFVIIa dose groups and compared them with the placebo group. We defined presence of IVH as any blood in any part of the ventricular system. The definition of IVH growth was an increase in IVH volume of 2 ml or greater between the baseline and 24-hour CT scans, which represents six times the inter-reader variability. Multivariate analyses were performed including and excluding patients with external ventricular drainage (EVD), whether placed simply for intracranial pressure monitoring or for treatment of obstructive hydrocephalus, to assess the impact of EVD on outcomes.
Statistical Analyses
Analyses were performed to identify factors predictive of presence of IVH; increase in IVH in the first 24 hours of the study; poor clinical outcome (mRS, 4-6); and mortality. In each case, a logistic regression model was applied. Covariates were analyzed individually (univariate analysis) to find possible significant predictors for the outcome under evaluation. The covariates found to be significant at P values less than 0.25 in these univariate analyses were then included in a multivariate model. This multivariate model was reduced by successively removing the least significant covariate from the model. All covariates with P values less than 0.10 were kept in the final model.
The covariates examined were time from symptom onset to baseline CT, time from symptom onset to dosing, time from baseline CT to dosing, ICH volume at baseline, GCS score at baseline, age, body temperature, systolic blood pressure, diastolic blood pressure, mean arterial pressure (MAP), presence of IVH increase, size of IVH increase, IVH present at baseline, IVH present at any time point, IVH volume at baseline, body mass index (Ͼ25 versus Յ25), history of diabetes or hypertension, Asian versus non-Asian, fibrinogen level, platelet count, sex, location of hemorrhage (basal ganglia, thalamic, other), and treatment (any dose rFVIIa versus placebo). Missing CT scan values were replaced by the closest available CT scan, not including the baseline, where possible.
RESULTS
Three hundred seventy-four patients out of the 399 in the original study were included in this analysis. Twenty-five patients were excluded because of missing values because of death (n ϭ 7), incomplete CT images (n ϭ 4), hematoma evacuation before the 24-hour scan (n ϭ 9), or because of logistical reasons (n ϭ 5). For the remaining 374 patients included in this study, 41 (11%) had 24-hour CT scans performed outside the protocol time window (Ϯ 3 hr) and had a nonbaseline CT scan used in the current analyses. An EVD was placed within 24 hours in 7.6% (13 out of 170) of the IVH patients.
IVH Presence
Of the 374 patients, 170 (45%) had IVH at baseline or at 24 hours ( Table 1) . The proportion of patients with IVH present at baseline or 24-hours was 50% in placebo and 44% in the rFVIIa treated patients. An increase in IVH of more than 2 ml comparing baseline and 24-hour volume was seen in 17% of placebo patients and 10% of rFVIIa patients (P ϭ 0.037, in multivariate analysis reported later). Table 2 summarizes baseline characteristics of patients according to whether they presented with or developed IVH within 24 hours. Risk factors for the presence of IVH identified by logistic regression were an increase of age, baseline ICH volume, MAP values greater than 120 mmHg, and thalamic location of parenchymal blood ( Table 3) .
IVH Dynamics
In 12% (44 out of 374) of patients, there was an increase of more than 2 ml in volume between baseline and 24 hours ( Table 1) . Multivariate analyses revealed the following independent predictors for IVH growth: MAP higher than 120 mmHg (P ϭ 0.0078), ICH volume at baseline (P Ͻ 0.0001), IVH Figure 1 displays the relationship between increase of parenchymal blood and change of intraventricular blood volume for those patients who had IVH growth. The graph reflects that, for each additional 10 ml of intraparenchymal blood, there is an increase of IVH volume of approximately 2.3 ml (P ϭ 0.02).
Impact of IVH Growth on Outcome
To analyze the impact of IVH growth on outcome, we compared patients who had no IVH or no IVH growth (n ϭ 330) with patients who had IVH growth (n ϭ 44). Poor clinical outcome (mRS, 4-6) was significantly different at Day 90, occurring in 93% of patients with IVH growth and 50% of patients without IVH growth (P ϭ 0.04) (Fig. 2) . Mortality was also significantly different between these two groups: 59 and 14% (P Ͻ 0.0001). These analyses were adjusted for other significant predictors found in the logistic regression analyses. For poor outcome, we found the following covariates significant: age (P Ͻ 0.0001), baseline GCS (P Ͻ 0.0001), ICH volume at baseline (P ϭ 0.0007), IVH increase greater than 2 ml (P ϭ 0.0405), IVH present at baseline or 24 hours (P ϭ 0.0014), and treatment with placebo (P ϭ 0.0327) ( Table 5 ). Predictors of mortality were age (P ϭ 0.0194), baseline GCS (P Ͻ 0.0001), history of hypertension (P ϭ 0.0004), baseline ICH volume (P ϭ 0.0003), and IVH increase greater than 2 ml (P Ͻ 0.0001) ( Table 6 ).
DISCUSSION
The results of the analysis reported here confirm the previous observations that as many as half of the patients with spontaneous ICH develop IVH within 24 hours of symptom onset, a finding associated with increased morbidity and worse clinical outcomes (Fig. 2) (3, 15, 25-27 ). In the current analyses, increase of age, additional milliliters of ICH volume, and baseline MAP greater than 120 mmHg increased the likelihood of IVH being present on the baseline or 24-hour CT scan study. This confirms previous data demonstrating that ICH volume predicts IVH occurrence (2, 10, 24, 26). To our knowledge, this is the first study that prospectively demonstrated the predictive value of elevated blood pressure at baseline on an increased probability of growth of intraventricular blood associated with poor outcome. Leira et al. (12) found early neurological deterioration to be associated with IVH and highest systolic blood pressure at 
FIGURE 1. Graph showing the dynamics of intraventricular and parenchymal hemorrhage, as well as the best linear fit of IVH change to ICH change (baseline to 24-hr CT scan).
48 hours. In particular, the influence of elevated MAP at baseline has an important impact on current treatment strategies because it is a modifiable risk factor. The American Heart Association guidelines recommend treatment of elevated MAP if greater than 130 mmHg (1). Qureshi et al. (23) found growth of ICH to be only 9% when they maintained blood pressure even lower (systolic blood pressure below 160 mmHg and diastolic blood pressure below 90 mmHg). These results support the need for further studies on blood pressure treatment in ICH. In addition, ICH location was a significant predictor of IVH risk; we found that thalamic ICH location nearly tripled the risk of IVH ( Table 3) . These findings support current hypotheses on the mechanism of secondary IVH in patients with spontaneous ICH and its impact on outcomes. Brott et al. (3) speculated that hemorrhages originating in the periventricular regions are more likely to expand toward the nearby ventricle because the fluid spaces are more compressible than the surrounding brain parenchyma as CSF redistributes extracranially. This is supported by the results from Young et al. (27) , who found that thalamic hemorrhages, with their proximity to the ventricles, were associated with larger IVH volume and worse outcomes; and Tuhrim et al. (26) who showed a close correlation between volume of baseline parenchymal and intraventricular blood and outcome. Similarly, Diringer et al. (5) found that deep hemorrhages were associated with increased incidence of obstructive hydrocephalus, which results in raised intracranial pressure above the direct effects attributed to the hemorrhage volume.
IVH growth was significantly associated with increased mortality and poorer clinical outcome. Furthermore, outcome was not only worse in those patients who developed an IVH (compared with those who did not have IVH at any time point), but it was significantly worse when patients with IVH had intraventricular blood volume growth.
The correlation between IVH and increased morbidity is not clearly understood. Certainly, blockage of CSF outflow with obstructive hydrocephalus and the subsequent increase of intracranial pressure (and, therefore, reduction in cerebral perfusion pressure) plays an important prognostic role. Hydrocephalus was shown to be an independent predictor of outcome in spontaneous ICH (5) . The concept is further supported by the observation that IVH volume may be associated with a commensurate decrease in global cerebral blood flow (14) . Interestingly, in other studies, outcome did not differ in those patients treated with a ventriculostomy or EVD (5, 27) . This may support the hypothesis that the enhanced morbidity associated with IVH is attributable, at least in part, to the pressure exerted by the clot on periventricular structures (26) . This emphasizes the possible impact of a treatment that prevents IVH or limits further IVH expansion. To our knowledge, this is the first evaluation on the dynamics of IVH in a large prospective trial. Our data suggest that 12% of patients who develop an IVH will show a further increase of intraventricular blood. In fact, our analyses may underestimate the extent of IVH expansion because we chose a conservative threshold of 2 ml increase. The risk of IVH growth was tripled by a MAP above 120 mmHg, quadrupled by the presence of IVH at baseline (Table 4) , and increased with every ml of ICH volume at baseline.
Even more important, the risk of further increases in IVH volume was reduced when patients received rFVIIa. A greater percentage of rFVIIa-treated patients had a favorable functional outcome (mRS, 0-3) across all groups (Fig. 2) , although these results did not reach statistical significance. This is in agreement with the results of the primary analysis of this study, which found that rFVIIa treatment significantly reduced 90-day mortality and reduced the percentage of patients with a poor clinical outcome (13) . These results, therefore, suggest that the clinical effect of rFVIIa on functional outcome in patients with ICH may be, at least in part, caused by its effects on both ICH and IVH expansion.
Previous studies tried to accelerate intraventricular clot resolution (either by EVD to treat obstructive hydrocephalus or in combination with intraventricular thrombolysis). We did not prospectively obtain information on the distribution of intraventricular blood or the occurrence of obstructive hydrocephalus. Thirteen out of 170 patients with IVH were treated with an EVD. Comparison of the different analyses with and without patients who had received an EVD revealed that this did not influence the overall results on treatment effect, mortality, or outcome. However, this comparison was limited by the numbers of patients in the EVD group. These observations are consistent with other studies that did not observe a beneficial effect of ventricular drainage in patients with spontaneous ICH (5, 27) . Principally, the results of this current analysis represent a potential new therapeutic approach to the treatment of ICH.
Intraventricular thrombolysis in primary IVH unrelated to ICH does lead to an improvement of 30-day survival (19) . Intraventricular thrombolysis has been shown to speed up clot resolution in patients with secondary IVH after subarachnoid hemorrhage and after spontaneous ICH (6, 21) . However, intraventricular thrombolysis may be associated with an increased risk of symptomatic bleeding (20) . In contrast, the current study used a hemostatic agent in essence as "prophylaxis" for intraparenchymal expansion and intraventricular extension of parenchymal blood.
The results of this study should be considered in the light of a number of limitations. First, this planned secondary analysis was not powered to detect effects of rFVIIa treatment on IVH volume changes and outcome. However, the trend of a lower mortality and better outcome was consistently observed in the active treatment groups whether IVH was present at baseline or not (Fig. 2) . Second, CT scan data were missing for 25 (6.3%) patients. However, because the missing data were approximately evenly distributed between the four treatment groups, it is unlikely that these omissions would have significantly impacted the results of the analyses.
CONCLUSIONS
The results of these analyses provide further confirmation that the presence of IVH within the first few days after ICH is associated with increased mortality and an overall worse clinical outcome. In addition, an increase in IVH over the first 24 hours after the symptom onset of ICH seems to be associated with a particularly poor prognosis. The risk of IVH is particularly high in patients with thalamic hemorrhages, in which the ICH is in close proximity to the ventricular system. Similarly, the risk of IVH increase is particularly high in patients who present with IVH on the initial CT scan. Treatment with rFVIIa reduced the risk of increase in IVH (above a 2 ml threshold) compared with placebo and appeared to reduce the risk of poor clinical outcome and death. These data suggest that rFVIIa therapy may reduce morbidity and mortality associated with ICH, at least in part through its impact on limiting IVH growth in the early period after ICH. Further studies involving expanded sample sizes are warranted to confirm the impact of rFVIIa on IVH secondary to ICH and to further explore IVH dynamics and the effects of obstructive hydrocephalus and EVD treatment on outcomes.
